HPV jab may combat cervical cancer in adults using technology similar to AstraZeneca COVID vaccine

The ground-breaking technology behind the Oxford-AstraZeneca COVID vaccine could be used to combat cervical cancer, potentially eradicating early symptoms of the disease before it progresses.
Last updated:

HPV jab that uses technology similar to AstraZeneca’s COVID vaccine may combat cervical cancer in adults

  • Trials are underway in several NHS hospitals, with women over 50 testing positive for pre-cancerous tissue on their cervix, a specially designed HPV jab.
  • Researchers will investigate whether pre-cancerous tissue is still on the cervix along with any traces of HPV (human papillomavirus), an infection almost always present when women develop this cancer.
  • The trial, called Apollo, includes a vaccine called VTP-200, which targets HPV.
  • It differs from the HPV jab given to adolescents in that it uses an inactivated chimpanzee adenovirus – the same technology as the AstraZeneca COVID jab

Oxford-AstraZeneca The grassroots technology behind the COVID vaccine could be used to combat cervical cancer, potentially eradicating early symptoms of the disease before it progresses.

A trial is underway in several NHS hospitals that let women over 50 test positive for pre-cancerous tissue on their cervix, a specially designed HPV jab.

After a year, researchers will examine whether pre-cancerous tissue is still on the cervix along with any traces of HPV (human papillomavirus), an infection that is almost always present when women develop this cancer. .

The trial, called Apollo, involves a vaccine called VTP-200, which targets HPV, but differs from the HPV jab given to adolescents because it uses an inactivated chimpanzee adenovirus – a technology similar to the AstraZeneca Covid jab.

The ground-breaking technology behind the Oxford-AstraZeneca COVID vaccine could be used to combat cervical cancer, potentially eradicating early symptoms of the disease before it progresses.

The ground-breaking technology behind the Oxford-AstraZeneca COVID vaccine could be used to combat cervical cancer, potentially eradicating early symptoms of the disease before it progresses.

A trial is underway in several NHS hospitals that let women over 50 test positive for pre-cancerous tissue on their cervix, a specially designed HPV jab.  Above, an example of HPV (human papillomavirus) - an infection that is almost always present when women develop this cancer

A trial is underway in several NHS hospitals that let women over 50 test positive for pre-cancerous tissue on their cervix, a specially designed HPV jab. Above, an example of HPV (human papillomavirus) – an infection that is almost always present when women develop this cancer

It is made by Vacitech, a company co-founded by Dame Sarah Gilbert, one of the leading creators of the COVID vaccine.

It is hoped that if it succeeds in eliminating both of these warning signs, the treatment could replace the invasive surgery to remove the worrying tissue that thousands of women face each year.

Professor Pierre Martin-Hirsch, a gynecologist at Lancashire Teaching Hospitals NHS Trust, who was involved in the trial, says: ‘If we can treat the early symptoms of cervical cancer without surgery, it will make a huge difference to the well-being of a lot of women. .’ , ‘We believe this vaccine can be the solution.’

Cervical cancer, which affects around 3,200 women each year, is one of the best controlled cancers in the UK.

This is mainly due to the success of the large-scale screening programme, in which women undergo smear tests.

It has reduced the number of cases by about 60 percent since it was introduced in 1988.

Screening looks for symptoms of HPV, a common virus that causes most cervical cancers.

When HPV is present, doctors look to see if any pre-cancerous cell changes have occurred on the cervix.

If they have — and doctors believe these changes to be cancerous — a procedure to burn the cells or remove part of the cervix may be needed.

While almost always safe and effective, surgery carries risks to the woman’s reproductive system, increasing the risk of subsequent miscarriage and infertility.

Advertisement

,